Chemistry & Biology
Volume 17, Issue 2, 26 February 2010, Pages 123-134
Journal home page for Chemistry & Biology

Article
Discovery of Dual Inhibitors of the Immune Cell PI3Ks p110δ and p110γ: a Prototype for New Anti-inflammatory Drugs

https://doi.org/10.1016/j.chembiol.2010.01.010Get rights and content
Under an Elsevier user license
open archive

Summary

PI3Kδ and PI3Kγ regulate immune cell signaling, while the related PI3Kα and PI3Kβ regulate cell survival and metabolism. Selective inhibitors of PI3Kδ/γ represent a potential class of anti-inflammatory agents lacking the antiproliferative effects associated with PI3Kα/β inhibition. Here we report the discovery of PI3Kδ/γ inhibitors that display up to 1000-fold selectivity over PI3Kα/β and evaluate these compounds in a high-content inflammation assay using mixtures of primary human cells. We find selective inhibition of only PI3Kδ is weakly anti-inflammatory, but PI3Kδ/γ inhibitors show superior inflammatory marker suppression through suppression of lipopolysaccharide-induced TNFα production and T cell activation. Moreover, PI3Kδ/γ inhibition yields an anti-inflammatory signature distinct from pan-PI3K inhibition and known anti-inflammatory drugs, yet bears striking similarities to glucocorticoid receptor agonists. These results highlight the potential of selectively designing drugs that target kinases with shared biological function.

Highlights

► Conformationally specific PI3Kδ/γ inhibitors do not inhibit PI3Kα/β ► Specific PI3Kδ/γ inhibitors are active and potent in cells ► Selective PI3Kδ/γ inhibition lowers TNFα secretion and E-selectin expression ► Selective PI3Kδ/γ inhibition functionally resembles GR agonist prednisolone

CHEMBIO
SIGNALING

Cited by (0)

5

Present address: The Rockefeller University, 1230 York Avenue, New York, NY 10021, USA